Benefit-risk balance of orlistat is positive, says EMA
This article was originally published in Scrip
Executive Summary
The EMA is satisfied that the benefits of orlistat (Roche's prescription product Xenical and GSK's half-dose OTC version Alli) outweigh the risks for treating obese or overweight patients with a body mass index of 28 KG/m2 or more.